Azosemide

Identification

Name
Azosemide
Accession Number
DB08961
Type
Small Molecule
Groups
Investigational
Description

Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

Structure
Thumb
Synonyms
  • 2-chloro-5-(1H-tetrazol-5-yl)-N4-2-thenylsulfanilamide
  • 5-(4'-chloro-5'-sulfamoyl-2'-thenylaminophenyl)tetrazole
  • azosemida
  • azosémide
  • azosemidum
Categories
UNII
MR40VT1L8Z
CAS number
27589-33-9
Weight
Average: 370.838
Monoisotopic: 370.007342713
Chemical Formula
C12H11ClN6O2S2
InChI Key
HMEDEBAJARCKCT-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN6O2S2/c13-9-5-10(15-6-7-2-1-3-22-7)8(12-16-18-19-17-12)4-11(9)23(14,20)21/h1-5,15H,6H2,(H2,14,20,21)(H,16,17,18,19)
IUPAC Name
2-chloro-5-(2H-1,2,3,4-tetrazol-5-yl)-4-[(thiophen-2-ylmethyl)amino]benzene-1-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CS2)C(=C1)C1=NNN=N1

Pharmacology

Indication
Not Available
Pharmacodynamics

Diuretic affects upon oral administration match those of furosemide. However, upon intravenous administration azosemide displays 5.5 to 8 times greater effect.

Mechanism of action

Exact mechanism of action is unclear. However, it acts primarily on the loop of Henle, in both the medullary and cortical segments of the thick ascending limb.

Absorption

Peak plasma concentrations are achieved in 3-4 hours when azosemide is administered to healthy humans in a fasting state. There is an absorption lag time of approximately 1 hour. Oral bioavailability estimated to be 20.4%

Volume of distribution

Poor affinity for human tissue. Small apparent post-pseudodistribution Vd of 0.262 l/kg.

Protein binding

> 95% 4% protein binding to 4% human serum albumin at azosemide concentrations of 10-100ug/ml, using equilibrium dialysis.

Metabolism

Considerable first pass metabolism which makes parentral administration more effective than oral administration. Eleven metabolites of azosemide were found in rats, but only azosemide and its glucuronide were detected in humans.

Route of elimination

Total body clearance 112ml/min. Renal clearance 41.6ml/min. Actively secreted in the renal proximal tubule of humans. This may or may not involve a nonspecific organic acid secretory pathway. There is thus a potential for disease states and other organic acids such as NSAIDs which affect the organic acid transport pathway to affect the efficacy of azosemide.

Half life

Terminal half life 2-3 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Azosemide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Azosemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Azosemide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Azosemide.Experimental, Illicit
AbediterolAbediterol may increase the hypokalemic activities of Azosemide.Investigational
AceclofenacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Azosemide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Azosemide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Azosemide.Approved
AlcuroniumAzosemide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Azosemide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Azosemide.Approved, Illicit
AllopurinolThe risk or severity of adverse effects can be increased when Azosemide is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Alminoprofen.Experimental
AloxiprinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Azosemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Azosemide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Azosemide.Approved
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Azosemide.Approved, Investigational, Vet Approved
Aminosalicylic AcidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Aminosalicylic Acid.Approved
AndrographolideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Azosemide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Azosemide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Azosemide.Investigational
AnisodamineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Azosemide can be decreased when used in combination with Apocynin.Investigational
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Azosemide.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Azosemide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Azosemide.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Azosemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Azosemide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Azosemide.Investigational
AtracuriumAzosemide may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateAzosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Azosemide.Approved, Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Azosemide.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Azosemide.Experimental
BenazeprilAzosemide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Benzydamine.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Azosemide.Experimental, Illicit, Withdrawn
BitolterolBitolterol may increase the hypokalemic activities of Azosemide.Withdrawn
BromfenacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Azosemide.Approved
BufexamacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bumadizone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Azosemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azosemide.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Azosemide.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Azosemide.Approved
CandoxatrilAzosemide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilAzosemide may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Azosemide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Azosemide.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Azosemide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Azosemide.Approved, Investigational
CilazaprilAzosemide may increase the hypotensive activities of Cilazapril.Approved
CisatracuriumAzosemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Azosemide is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Azosemide.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Azosemide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Azosemide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Azosemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Azosemide.Approved
ClonixinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Clonixin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Azosemide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Azosemide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Azosemide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Azosemide.Approved, Investigational
CurcuminThe therapeutic efficacy of Azosemide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azosemide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Azosemide is combined with Cymarin.Experimental
DecamethoniumAzosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Azosemide.Approved, Investigational
DelaprilAzosemide may increase the hypotensive activities of Delapril.Experimental
DersalazineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Dersalazine.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Azosemide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Azosemide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Azosemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Azosemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Azosemide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Azosemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Azosemide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azosemide.Approved, Investigational
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Azosemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azosemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Azosemide.Approved, Investigational
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Azosemide.Experimental
DiclofenacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DifenpiramideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Azosemide.Approved
DiflunisalThe therapeutic efficacy of Azosemide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Azosemide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Azosemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Azosemide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Azosemide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Azosemide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azosemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Azosemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Azosemide.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Azosemide.Investigational, Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Azosemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Azosemide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Azosemide.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Azosemide is combined with Dofetilide.Approved, Investigational
Domoic AcidAzosemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideAzosemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Azosemide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Azosemide.Experimental
DroxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Azosemide.Approved, Investigational
DuvelisibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Azosemide can be decreased when used in combination with E-6201.Investigational
EnalaprilAzosemide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAzosemide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Azosemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Azosemide can be decreased when used in combination with Epirizole.Approved
EquileninEquilenin may increase the hypokalemic activities of Azosemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Azosemide.Approved
EstroneEstrone may increase the hypokalemic activities of Azosemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Azosemide.Approved
EtafedrineEtafedrine may increase the hypokalemic activities of Azosemide.Approved
EtanerceptThe therapeutic efficacy of Azosemide can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ethenzamide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Azosemide.Approved, Illicit
EtodolacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Azosemide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Azosemide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe therapeutic efficacy of Azosemide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Azosemide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Azosemide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Azosemide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Azosemide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Azosemide.Approved, Investigational
FlunixinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Azosemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Azosemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Azosemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Azosemide.Approved, Investigational
FluprednideneFluprednidene may increase the hypokalemic activities of Azosemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Azosemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Azosemide.Approved
FlurbiprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Azosemide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Azosemide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Azosemide.Approved
FormestaneFormestane may increase the hypokalemic activities of Azosemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Azosemide.Approved, Investigational
FoscarnetAzosemide may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilAzosemide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Azosemide.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Azosemide.Approved
GallamineAzosemide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideAzosemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Azosemide.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Azosemide.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Azosemide.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Azosemide is combined with Gitoformate.Experimental
GuacetisalThe therapeutic efficacy of Azosemide can be decreased when used in combination with Guacetisal.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Azosemide.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Azosemide.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Azosemide can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Azosemide.Approved, Illicit, Investigational
HexoprenalineHexoprenaline may increase the hypokalemic activities of Azosemide.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Higenamine.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Azosemide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Azosemide.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Azosemide.Vet Approved
IbuprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Azosemide can be decreased when used in combination with Icatibant.Approved, Investigational
ImidaprilAzosemide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Azosemide.Approved
IndobufenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Indoprofen.Withdrawn
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Azosemide.Experimental
IsoetarineIsoetarine may increase the hypokalemic activities of Azosemide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Azosemide.Approved, Investigational
IsoxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Isoxicam.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Azosemide.Investigational
IvabradineAzosemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Azosemide.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Azosemide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ketorolac.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Azosemide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Leflunomide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azosemide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azosemide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Azosemide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Azosemide.Approved
LisinoprilAzosemide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Azosemide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Azosemide.Illicit
LonazolacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Azosemide.Approved
LoxoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Azosemide can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Azosemide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Azosemide is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Azosemide.Approved
Mefenamic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Azosemide.Vet Approved
MeloxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Azosemide.Experimental
MesalazineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Azosemide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Azosemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Azosemide.Approved, Illicit
MethotrexateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Methotrexate.Approved
Methyl salicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Azosemide is combined with Metildigoxin.Experimental
MetocurineAzosemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideAzosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Azosemide.Experimental
MivacuriumAzosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilAzosemide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Azosemide.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Azosemide.Approved
NaproxenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Azosemide.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Azosemide.Experimental
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Azosemide.Approved, Vet Approved
NeosaxitoxinAzosemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nepafenac.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Azosemide.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Azosemide.Experimental
NifenazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nitroaspirin.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Azosemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Azosemide.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Azosemide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Azosemide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Azosemide.Approved
OlopatadineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatAzosemide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Azosemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Azosemide.Approved
OrgoteinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Azosemide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Oxaprozin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azosemide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azosemide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PalmidrolThe therapeutic efficacy of Azosemide can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumAzosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Azosemide.Approved
ParecoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Parecoxib.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Azosemide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Parthenolide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide.Approved, Vet Approved
PerindoprilAzosemide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Azosemide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Azosemide.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Azosemide.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Azosemide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Azosemide.Experimental
Phenyl aminosalicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Azosemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Azosemide.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Azosemide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PipecuroniumAzosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Azosemide.Approved
PirfenidoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Azosemide.Approved, Investigational
PiroxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Pirprofen.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Azosemide.Investigational
PranoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Azosemide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Azosemide.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Azosemide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Azosemide.Approved, Experimental, Investigational
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Azosemide.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Azosemide.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Azosemide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Azosemide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
PTC299The therapeutic efficacy of Azosemide can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Azosemide.Experimental
PyrantelAzosemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilAzosemide may increase the hypotensive activities of Quinapril.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Azosemide.Approved
RamiprilAzosemide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumAzosemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azosemide.Approved
RescinnamineAzosemide may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolThe therapeutic efficacy of Azosemide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Azosemide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Azosemide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Azosemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Azosemide.Approved, Investigational
RocuroniumAzosemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Azosemide.Approved
SalsalateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Salsalate.Approved
SemapimodThe therapeutic efficacy of Azosemide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Azosemide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Azosemide can be decreased when used in combination with Serrapeptase.Investigational
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Azosemide.Investigational
Sodium phosphateAzosemide may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilAzosemide may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Azosemide can be decreased when used in combination with SRT501.Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Azosemide.Approved, Vet Approved
SuccinylcholineAzosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Azosemide can be decreased when used in combination with Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Azosemide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Azosemide can be decreased when used in combination with Suxibuzone.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Azosemide.Approved
TarenflurbilThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tarenflurbil.Investigational
TemocaprilAzosemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Azosemide.Approved
TeriflunomideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Azosemide.Experimental
TinoridineThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tinoridine.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Azosemide.Approved, Withdrawn
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Azosemide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tolmetin.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Azosemide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Azosemide.Approved, Investigational
TrandolaprilAzosemide may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tranilast.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Azosemide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Triptolide.Investigational
Trolamine salicylateThe therapeutic efficacy of Azosemide can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarineAzosemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Azosemide.Approved
ValdecoxibThe therapeutic efficacy of Azosemide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
VecuroniumAzosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VilanterolVilanterol may increase the hypokalemic activities of Azosemide.Approved
ZaltoprofenThe therapeutic efficacy of Azosemide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Azosemide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilAzosemide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Azosemide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041831
PubChem Compound
2273
PubChem Substance
347827814
ChemSpider
2186
ChEBI
31248
ChEMBL
CHEMBL1097235
Wikipedia
Azosemide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0929 mg/mLALOGPS
logP2.36ALOGPS
logP2.38ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.38ChemAxon
pKa (Strongest Basic)-0.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area126.65 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity102.08 m3·mol-1ChemAxon
Polarizability34.56 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyltetrazoles and derivatives. These are compounds containing a phenyltetrazole skeleton, which consists of a tetrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Tetrazoles
Direct Parent
Phenyltetrazoles and derivatives
Alternative Parents
Aminobenzenesulfonamides / Benzenesulfonyl compounds / Phenylalkylamines / Aniline and substituted anilines / Secondary alkylarylamines / Chlorobenzenes / Organosulfonamides / Aryl chlorides / Thiophenes / Aminosulfonyl compounds
show 6 more
Substituents
Aminobenzenesulfonamide / Phenyltetrazole / Benzenesulfonamide / Benzenesulfonyl group / Aniline or substituted anilines / Phenylalkylamine / Chlorobenzene / Halobenzene / Secondary aliphatic/aromatic amine / Aralkylamine
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, thiophenes, tetrazoles, monochlorobenzenes (CHEBI:31248)

Drug created on May 30, 2014 09:41 / Updated on June 02, 2018 08:14